Miacalcin (Calcitonin Salmon Nasal)

Miacalcin (Calcitonin Salmon Nasal) is filed as Calcitonin. The sections below restate public label fields stored for this profile.

Class
Calcitonin
Generic name
Calcitonin Salmon Nasal
Route
INTRAMUSCULAR
Dosage forms
• Serious hypersensitivity reactions, including reports of fatal anaphylaxis have been reported. Consider skin testing prior to treatment in patients with suspected hypersensitivity to calcitonin salmon ( 5.1 ) • Hypocalcemia has been reported. Ensure adequate intake of calcium and vitamin D ( 5.2 ) • Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk of overall malignancies in calcitonin salmon-treated patients ( 5.3 , 6.1 ) • Circulating antibodies to calcitonin salmon may develop, and may cause loss of response to treatment ( 5.4 )
Generic available
Yes
Manufacturer
Mylan Institutional LLC

Approved uses

Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: • Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 )

How it works

Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Serious hypersensitivity reactions, including reports of fatal anaphylaxis have been reported. Consider skin testing prior to treatment in patients with suspected hypersensitivity to calcitonin-salmon ( 5.1 ) Hypocalcemia has been reported. Ensure adequate intake of calcium and vitamin D ( 5.2 ) Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk of overall malignancies in calcitonin-salmon-treated patients ( 5.3 , 6.1 ) Circulating antibodies to calcitonin-salmon may develop, and may cause loss of response to treatment ( 5.4 ) 5.1 Hypersensitivity Reactions Serious hypersensitivity reactions have been reported in patients receiving Miacalcin injection, e.g., bronchospasm, swelling of the tongue or throat, anaphylactic shock, and death due to anaphylaxis. Appropriate medical support and monitoring measures should be readily available when Miacalcin injection is administered. If anaphylaxis or other severe hypersensitivity/allergic reactions occur, initiate appropriate treatment [see Contraindications (4) ]. For patients with suspected hypersensitivity to calcitonin-salmon, skin testing should be considered prior to treatment utilizing a dilute, sterile solution of Miacalcin injection. Healthcare providers may wish to refer patients who require skin testing to an allergist. A detailed skin testing protocol is available from the Sebela Pharmaceuticals Inc. Medical Information Department. 5.2 Hypocalcemia Hypocalcemia associated with tetany (i.e., muscle cramps, twitching) and seizure activity has been reported with Miacalcin injection therapy. Hypocalcemia must be corrected before initiating therapy. Other disorders affecting mineral metabolism (such as vitamin D deficiency) should also be effectively treated. In patients at risk for hypocalcemia, provisions for parenteral calcium administration should be available during the first several administrations of calcitonin-salmon and serum calcium and symptoms of hypocalcemia should be monitored. Use of Miacalcin injection for the treatment of Paget’s disease or postmenopausal osteoporosis is recommended in conjunction with an adequate intake of calcium and vitamin D [see Dosage and Administration (2.5) ]. 5.3 Malignancy In a meta-analysis of 21 randomized, controlled clinical trials with calcitonin-salmon (nasal spray or investigational oral formulations), the overall incidence of malignancies reported was higher among calcitonin-salmon-treated patients (4.1%) compared with placebo-treated patients (2.9%). This suggests an increased risk of malignancies in calcitonin-salmon-treated patients compared to placebo-treated patients. It is not possible to exclude an increased risk when calcitonin-salmon is administered long-term subcutaneously, intramuscularly, or intravenously. The benefits for the individual patient should be carefully considered against possible risks [see Adverse Reactions (6.1) ]. 5.4 Antibody Formation Circulating antibodies to calcitonin-salmon have been reported with Miacalcin injection. The possibility of antibody formation should be considered in any patient with an initial response to Miacalcin injection who later stops responding to treatment [see Adverse Reactions (6.3) ]. 5.5 Urine Sediment Abnormalities Coarse granular casts and casts containing renal tubular epithelial cells were reported in young adult volunteers at bed rest who were given injectable calcitonin-salmon to study the effect of immobilization on osteoporosis. There was no other evidence of renal abnormality and the urine sediment normalized after calcitonin-salmon was stopped. Periodic examinations of urine sediment should be considered.

Contraindications

Hypersensitivity to calcitonin salmon or any of the excipients. Reactions have included anaphylaxis with death, bronchospasm, and swelling of the tongue or throat [see Warnings and Precautions (5.1) ] .

Common side effects

Tions are nausea with or without vomiting (10%); Injection site inflammation (10%)

Adverse reactions

The following serious adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity Reactions, including anaphylaxis [see Warnings and Precautions ( 5.1 ) ] Hypocalcemia [see Warnings and Precautions ( 5.2 ) ] Malignancy [see Warnings and Precautions ( 5.3 ) ]

Dosage and administration

Symptomatic Paget’s disease of bone: 100 USP Units daily. Ensure adequate calcium and vitamin D intake ( 2.1 , 2.5 ) • Hypercalcemia: start with 4 USP Units/kg body weight every 12 hours. Increase to 8 USP Units/kg every 12 hours if no improvement in 1-2 days. Increase further to 8 USP Units/kg every 6 hours if no improvement after 2 more days ( 2.2 ) • Postmenopausal osteoporosis: 100 USP Units daily. Ensure adequate calcium and vitamin D intake ( 2.3 , 2.5 )

Drug interactions

No formal drug interaction studies have been performed with Miacalcin injection. Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment.

Common questions

What is Miacalcin approved to treat?

According to its FDA label, Miacalcin (Calcitonin Salmon Nasal) is approved for: Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alte… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Miacalcin?

Miacalcin (Calcitonin Salmon Nasal) belongs to the Calcitonin class of medications.

What form does Miacalcin come in?

The FDA label lists Miacalcin (Calcitonin Salmon Nasal) as: Serious hypersensitivity reactions, including reports of fatal anaphylaxis have been reported. Consider skin testing prior to treatment in patients with suspected hypersensitivity to calcitonin salmon ( 5.1 ) • Hypocalcemia has been reported. Ensure adequate intake of calcium and vitamin D ( 5.2 ) • Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk of overall malignancies in calcitonin salmon-treated patients ( 5.3 , 6.1 ) • Circulating antibodies to calcitonin salmon may develop, and may cause loss of response to treatment ( 5.4 ); intramuscular route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Miacalcin?

Yes. A generic version of Miacalcin (Calcitonin Salmon Nasal) is available in the U.S. Ask your pharmacist about substitution.

Does Miacalcin have a Boxed Warning?

Our ingest of the FDA label for Miacalcin (Calcitonin Salmon Nasal) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Miacalcin cost?

Public CMS NADAC pricing for Miacalcin (Calcitonin Salmon Nasal) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Miacalcin currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Miacalcin (Calcitonin Salmon Nasal) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Miacalcin approved by the FDA?

The FDA record lists the approval date for Miacalcin (Calcitonin Salmon Nasal) as 1986-07-03.

Who makes Miacalcin?

The FDA label lists Mylan Institutional LLC as a labeler/manufacturer of Miacalcin (Calcitonin Salmon Nasal). Multiple firms may market generics of the same molecule.

How should Miacalcin be stored?

The FDA label states: "How Supplied Miacalcin (calcitonin salmon, USP) Injection, Synthetic is available as a sterile solution in individual 2 mL multi-dose vials containing 200 USP Units per mL. NDC 72078-039-02 carton containing 1 x 2 mL mul…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…